Search research articles
Contact Us
Filters
Showing results (361-370 of 381) with videos related to
Page
of 39
Sort By:
Targeted Oncology
|
August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Clinical and Experimental Medicine
|
December 30, 2025
Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2<sup>EV</sup> project
Alessandro Rizzo, Zin W Myint, Francesco Ciccimarra, et al.
Frontiers in Immunology
|
May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Prostate Cancer and Prostatic Diseases
|
January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
JCO Global Oncology
|
October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Performance evaluation of RespiCast ensemble forecasts for primary care syndromic indicators of viral respiratory disease in Europe
Nicolò Gozzi, Corrado Gioannini, Paolo Milano, et al.
Page
of 39
Search research articles
Search
Showing results (361-370 of 381) with videos related to
Sort By:
Page
of 39
Targeted Oncology
|
August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Clinical and Experimental Medicine
|
December 30, 2025
Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2<sup>EV</sup> project
Alessandro Rizzo, Zin W Myint, Francesco Ciccimarra, et al.
Frontiers in Immunology
|
May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Prostate Cancer and Prostatic Diseases
|
January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
JCO Global Oncology
|
October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Performance evaluation of RespiCast ensemble forecasts for primary care syndromic indicators of viral respiratory disease in Europe
Nicolò Gozzi, Corrado Gioannini, Paolo Milano, et al.
Page
of 39